STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Shares of Alterity Therapeutics (NASDAQ:ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 ...
Hosted on MSN
Study backs Alterity’s innovative tool in diagnosing and monitoring MSA disease progression
Quality peer-reviewed publication highlights use of Alterity’s MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback